Dyne Therapeutics, Inc (DYN) Stock AnalysisDYNStock AnalysisDyne Therapeutics, Inc

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dyne Therapeutics is currently not a strong buy due to its recent earnings miss and significant net losses, but its strong cash reserves and upcoming FDA review could provide future upside. The current price is $25.07, and the company has a substantial cash reserve of $898.5 million, which can fund operations into Q2 2028. However, the risk is highlighted by a 61% increase in net loss for Q2 2026, reaching $178.56 million, which raises concerns about profitability.

8 analysts cover DYN: 4 rate it Buy, 4 Hold and 0 Sell. The average price target is 39.33.